Immutep Ltd. ADR is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company’s programs are built around LAG-3, an immune-regulating pathway used to modulate how the body’s immune system responds to disease. Its current pipeline includes product candidates such as eftilagimod alfa, IMP761, leramilimab, and GSK’781, which are being studied across multiple therapeutic areas. Immutep Ltd. ADR operates in the biotechnology segment of the healthcare market, where it contributes to the development of next-generation biologic treatments designed to address unmet medical needs. The company is headquartered in Sydney, Australia, and its work is centered on advancing specialized immunology-based therapies for use in oncology and autoimmune care.
WebsiteAustralia Square
Sydney, NSW, 2000
Australia
Media Release Pooled analysis of five efti trials (presented at ASCO 2026) reinforced efti's mechanism of action, tying immune activation to a 7.7-month median overall survival benefit in biological responders across four tumour types.IMP761, the only LAG-3 agonist antibody in clinical development, delivered encouraging first-in-human results (presented at EULAR 2026), meeting its primary safety endpoint and showing significant pharmacodynamic activity.Investigation into the futility outcome fro
SYDNEY, AUSTRALIA, July 24, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announced that an abstract for the investigator-initiated EFTISARC-NEO Phase II trial evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (“efti”), has been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place 23–27 October
SYDNEY, AUSTRALIA, July 14, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapies, today announced the grant of a new patent (number 12,673,088) entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent and Trademark Office (USPTO). This patent is the fourth in the series and follows the grant of the United States parent patent, first divisional patent, a
INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLCOutcomes continue to compare favourably with historical benchmarksPreliminary immune monitoring data indicate that patients treated with efti in TACTI-004 exhibited a different immune activation profile compared with previous studies TACTI-004 root cause analysis is ongoing with additional results expected in Q3 CY2026 SYDNEY, AUSTRALIA, July 13, 2026
Investors talking about IMMP also mention
What share of all stock conversation is about IMMP?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Attention | 0.01% -0.02 | 0% +0 | 0% +0 | 0% 0 |
Of the messages about IMMP that take a side, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Bullish | — | 0% -100 | 78.57% +11.9 | 82.54% -0.18 | ||
| Bearish | — | 100% new | 21.43% -11.9 | 17.46% +0.18 |
Of the messages about IMMP that carry a topic, what share is each?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Announcements | 0% | 0% | 88.46% | 46.73% | ||
| Technical Analysis | 100% | 100% | 11.54% | 14.43% | ||
| Controversies | 0% | 0% | 0% | 0.51% | ||
| Analysts | 0% | 0% | 0% | 7.27% | ||
| Earnings | 0% | 0% | 0% | 0% | ||
| Macro | 0% | 0% | 0% | 31.06% |
Of the messages about IMMP, what share comes from each group?
| 1 Day1D | 1 Week1W | 1 Month1M | 1 Year1Y | 50-Day MAclick to plot | 200-Day MAclick to plot | |
|---|---|---|---|---|---|---|
| Regulars | 2.68% | 1.44% | 11.51% | 41.05% | ||
| Newcomers | 97.32% | 98.56% | 88.49% | 58.95% |